Merck Keytruda Rivalry Surges as Ivonescimab Stumbles
Is the latest ivonescimab setback a temporary stumble or a turning point in the Merck Keytruda Rivalry for lung cancer dominance?
Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology bet?
Merck KGaA Forecast Warning: 2026 Profit Hit Looms
Is the latest Merck KGaA Forecast a temporary setback before new growth, or the start of a longer earnings squeeze? Merck KGaA Forecast: What the 2026 Guidance Really…